Ownership history in Almitas Capital LLC Β· 4 quarters on record
This page tracks every 13F SEC filing in which Almitas Capital LLC reported a position in Vistagen Therapeutics Inc (VTGN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Almitas Capital LLC outperformed the S&P 500 by +36.8% annually on this VTGN position. Average cost basis: $2.93. Maximum drawdown during holding period: β32.2%.
π₯ Exceptional β beat the S&P 500 by 36.8% per year on this position.
3 quarters analyzed
Best entry: $2.00 (2025 Q2) Β· Worst: $2.95 (2024 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
2 adds Β· 0 trims. Bought during 1 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.22% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size